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Aims The DoUble-blind Atorvastatin AmLodipine (DUAAL) trial investigated whether atorvastatin decreases ischaemia by
a vascular beneﬁt, independent of low-density lipoprotein cholesterol lowering, in patients with coronary artery
disease (CAD), both alone and in combination with the traditional anti-anginal therapy, amlodipine.
Methods
and results
Randomized, double-blind, parallel-group, multicountry trial (2 weeks run-in and 24 weeks active therapy) comparing
three treatments: amlodipine, atorvastatin, and amlodipine + atorvastatin; in 311 patients (78% male; mean age 62
years) with stable angina (≥2 attacks/week), CAD history, ≥3 transient myocardial ischaemia (TMI) episodes, and/
or ≥15 min ischaemia on 48 h ambulatory electrocardiographic (AECG) monitoring. Efﬁcacy variables were change
in TMI by AECG, exercise ischaemia, angina diary data, and inﬂammatory biomarkers at Week 26. There was a com-
parable, highly signiﬁcant decrease in TMI with amlodipine and atorvastatin, but no additional beneﬁt for the combi-
nation. More than 50% of patients became TMI-free in all three groups and this was accompanied by a comparable,
marked reduction in angina and nitroglycerin consumption. High-sensitivity C-reactive protein fell by 40% in patients
receiving atorvastatin but there was no change with amlodipine. Adverse events were comparable among groups.
Conclusion Atorvastatinwasaspotentananti-ischaemicagentasamlodipine.Futurestudiesofcombinationtherapieswillbeinstructive.
Clinical trial registration information: National clinical trial number: NCT00159718, protocol number A0531031 listed on
http://clinicaltrials.gov/.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Symptomatic coronary artery disease (CAD) in patients with
chronic stable angina is frequently treated by percutaneous
coronary intervention (PCI), but recent evidence has not shown
signiﬁcant improvement in mortality with this approach vs.
modern medical therapy.
1 It is increasingly clear that cardiovascular
outcomes depend on an understanding of the biology of athero-
sclerotic disease, which may involve vascular inﬂammation,
endothelial dysfunction, and plaque instability.
2 This has therefore
become a target for novel therapies.
Transient myocardial ischaemia (TMI) during daily life has been
linked to an increased risk of coronary events.
3 The pattern of
symptomatic and asymptomatic TMI has been used as a measure
of disease activity and response to therapies.
4,5 We have previously
shown that the long-acting calcium channel blocker, amlodipine
besylate, reduces TMI episodes over 24 h.
4,6 Recently, there has
been considerable interest in the potential vascular beneﬁts of
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(LDL-C).
7 In a study of 40 patients, lovastatin reduced ambulatory
TMI in patients with CAD. A larger study of 341 low-risk CAD
patients, AVERT, demonstrated that therapy with 80 mg of atorvas-
tatin daily reduced the incidence of ischaemic at least to a similar
level as that achieved by angioplasty followed by usual care.
8 In
patients with acute coronary syndromes and after myocardial infarc-
tion, the rapid outcome beneﬁt and fall in inﬂammatory biomarkers
achieved with statins suggest an effect on vascular biology.
9,10 This
has not been investigated in patients with stable CAD. The DoUble-
blind Atorvastatin AmLodipine (DUAAL) study was designed to
determine whether atorvastatin relieved TMI in a large cohort of
symptomatic CAD patients and to compare the effect of atorvasta-
tin with amlodipine. We investigated the time course of effects on
TMI and inﬂammatory biomarkers as a guide to mechanism of
action. Co-administration of amlodipine and atorvastatin has been
shown to increase nitric oxide and reduce oxidative stress in
vitro.
11 We therefore explored whether there was an additive
effect of combining atorvastatin with amlodipine.
Methods
Patient population
Men and women (aged 21–80 years) with clinically stable angina pec-
toris (≥2 attacks per week without change for ≥3 months prior to
study entry) were recruited from 46 clinical centres in 13 countries
(Appendix). Patients had to have a positive exercise test and documen-
tation of CAD deﬁned by ≥1 of the following: a positive thallium exer-
cise test; a coronary arteriogram demonstrating .70% narrowing of
≥1 major coronary artery; documentation of previous myocardial
infarction .2 months prior to the study; or history of coronary
artery bypass surgery or PCI. Total cholesterol was required to be
≥200 mg/dL (≥5.2 mmol/L). Angiograms were mandatory for all
females as false-positives can occur with other diagnostic procedures.
Exclusion criteria included congenital heart disease, uncontrolled
hypertension, standing systolic blood pressure (SBP) ,100 mmHg,
bradyarrhythmias (heart rate ,50 b.p.m.), greater than ﬁrst-degree
atrioventricular block, any medication known to interfere with the
electrocardiogram (ECG), intolerance or hypersensitivity to amlodi-
pine or atorvastatin, elevated creatine phosphokinase .3× upper
limit of normal, active liver disease or hepatic dysfunction, impaired
renal function, and total cholesterol ≥300 mg/dL (7.8 mmol/L). All
patients gave written, informed consent as approved by the insti-
tutional review boards of the study sites.
Eligible patients underwent 48 h of continuous ambulatory ECG
(AECG) monitoring and were included if they demonstrated ≥15 min
of ischaemia by ST-segment depression and/or three or more ischaemic
episodes. Patients were maintained on stable doses of all concomitant
cardiovascular medications; only patients who had received calcium
channel blockers within 2 weeks before screening and statins 4 weeks
before screening were excluded. Sublingual nitroglycerin was permitted
as required, but not for prophylaxis, and was recorded in patient diaries.
Study design
This was a parallel, randomized trial with a 2-week, single-blind, placebo
run-in phase followed by a double-blind treatment period. Eligible
patients were randomized in a 1:1:1 ratio using a computer-generated
randomization code to receive treatment with amlodipine, atorvastatin,
or both amlodipine and atorvastatin, once daily for 24 weeks (Figure 1).
Study medication was administered in a double-blind, double-
dummy design. Patients randomized to amlodipine received 5 mg/
day, and at Week 6, the dose was increased to 10 mg/day. Similarly
atorvastatin 10 mg was increased to 80 mg. In the combination arm,
the same titration schedule was undertaken for both agents.
The primary efﬁcacy endpoint was the number of ischaemic episodes
during 48 h AECG monitoring at Week 26. Secondary assessments
included changes from baseline to Week 18 in AECG ischaemic
episode number, as well as changes from baseline to Weeks 18, and
26 in bicycle exercise test variables, inﬂammatory biomarkers, angina
diary data, and lipid variables. Adverse events were also recorded.
Ambulatory electrocardiographic monitoring
Patients underwent 48 h AECG monitoring at Weeks 1, 18, and 26. A
calibrated two-channel AECG recording electrocardiographic appar-
atus (Rozinn Electronics model 151, Rozinn Electronics Inc., Glendale,
NY, USA) with a modiﬁed lead V3 and V5 or lead II was used. Record-
ings were analysed centrally by Cardiology Consultants (London, UK).
Episodes were identiﬁed by standard criteria. Episodes of sympto-
matic and asymptomatic TMI were not analysed separately by AECG
Figure 1 Study design. AECG, ambulatory electrocardiogram; ET, exercise test.
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were analysed in a blinded fashion both with respect to the patient
and study phase. For each episode of ST depression, time of onset,
number, duration, and severity were recorded.
Bicycle exercise testing
Bicycle ergometer exercise tests were performed at Weeks 2, 18, and
26 using a standard graded increase in workload. Heart rate and blood
pressure were measured. Total exercise time, reasons for stopping the
exercise, and the times to onset of ≥0.1 mV ST-segment depression
and to angina were recorded.
Blood assessments
High-sensitivity C-reactive protein, amyloid-A, and interleukin-6 levels
were determined at screening and at Weeks 6, 18, and 26. Lipid levels,
including total cholesterol, high-density lipoprotein cholesterol,
LDL-C, and triglycerides, were measured at Weeks 2, 6, 18, and 26.
Liver function tests were performed with central analysis.
Patient angina diaries
Angina diaries were completed daily by each patient from Weeks 0 to
26. Patients recorded the date, time, and duration of their angina epi-
sodes and the number of sublingual nitroglycerin tablets taken.
Statistical methods
The sample size was based on information from the Circadian Anti-
ischemia Program in Europe (CAPE II) trial.
6 A sample size of 300
(100 patients per treatment group) was calculated to have a power
of 80% to detect a difference in means of 0.6 episodes with a standard
deviation (SD) of 1.5 using a two-group t-test with a two-sided signiﬁ-
cance level of 0.05.
The efﬁcacy analyses were performed on the modiﬁed
intent-to-treat population, which was deﬁned as all randomized
patients with a baseline efﬁcacy measurement and ≥1 follow-up
measurement for the same variable. Missing measurements at post-
baseline visits were extrapolated using the last observation carried
forward (LOCF) method. Sensitivity analyses for the LOCF method
were performed using only data collected after Week 6, when the
dosage of study medication was increased. The results were identical
to those presented in this article. A statistical signiﬁcance level of
0.05 was used for all efﬁcacy analyses without adjusting for multiplicity.
Safety analyses were performed for all randomized patients who
received ≥1 dose of any study medication.
For efﬁcacy measurements with skewed distributions, including 48 h
AECG monitoring data, and inﬂammatory biomarkers, the overall
treatment differences for change from baseline were analysed using
the Kruskal–Wallis test. If the overall treatment effect was signiﬁcant,
a pair-wise comparison between treatment groups was performed
using the Wilcoxon rank-sum test. Within-treatment comparison
was performed using the Wilcoxon signed-rank test.
For the efﬁcacy measurements with approximate normal distributions
includinglipidproﬁles,anginadiarydata,andbicycleexercisetestdata,the
overall treatment differences on the change from baseline were analysed
using an analysis of covariance model with treatment as the main effect
and baseline as a covariate. If the overall treatment effect was signiﬁcant,
the pair-wise between-treatment comparison was performed using
least-squares means from the analysis of covariance model. Within-
treatment comparison was performed using a paired t-test.
The planned total duration of the bicycle exercise test (including
eight workload stages) was 16 min (960 s). If the onset of events,
.1 mm ST depression or onset of angina, was not observed by the
end of the test, the time to event was censored at that time point.
A log-rank test (including all three treatment groups) for the main
treatment effect was performed for the time to onset of .1m mS T
depression and onset of angina at Weeks 18 and 26. If the main treat-
ment effect was signiﬁcant, then all possible pair-wise treatment com-
parisons were performed using the log-rank test including the two
corresponding treatment groups.
The association between the change from baseline to Week 18 and
to Week 26 in the number of ischaemic episodes and the change from
baseline to Week 18 and to Week 26 in age, high-sensitivity C-reactive
protein, blood pressure, and total cholesterol were investigated using
stepwise regression models.
Statistical analysis was performed using SAS Version 8 (SAS Institute
Inc., Cary, NC, USA) according to the pre-speciﬁed statistical analysis
plan by the sponsor (Pﬁzer Inc.), under the guidance and supervision of
the independent steering committee.
Results
Study population
Of 625 patients who were screened, 312 were randomized and
311 (49.8%) received study drug (103 amlodipine, 104 atorvastatin,
and 104 combination therapy) (Figure 2). Of these, 29 patients
(9.3%) were excluded because of technical reasons and 94
(91.3%), 92 (88.5%), and 96 (92.3%) patients completed the
study with technically acceptable AECG data and few missing
data in the amlodipine, atorvastatin, and combination arms,
respectively. Overall 4% or less of the patients had missing data
on AECG, inﬂammatory biomarker, bicycle exercise test, lipids,
and patient diary data at Week 18. An additional 5% or less of
the patients had missing data at Week 26. In these individuals,
the Week 18 values were carried forward in the analyses.
Overall, ﬁve patients had a prior history of statin use (≥4 weeks
before screening), two in the amlodipine arm, one in the atorvas-
tatin arm, and two in the combination arm. However, no patient
took a statin in the 4-week period before screening and we
believe that such low prior usage is unlikely to inﬂuence the
results. Discontinuations were similar across arms (Figure 2).
Patient baseline characteristics in the three arms were compar-
able (Table 1). The majority were receiving intensive cardiovascular
drug treatment including b-blockers (80.7%), vasodilators (e.g.
long-acting nitrates) (62.4%), and aspirin (81.7%) at entry, and
minimal changes were made to background treatment during the
study (Table 2).
Transient myocardial ischaemia by
ambulatory electrocardiographic
monitoring
At Week 26, the median number of ischaemic episodes in all three
groups decreased signiﬁcantly (P , 0.001, within-treatment com-
parison) (Figure 3). There was no signiﬁcant difference among the
three treatment groups in the change from baseline to Week 26
in the number of ischaemic episodes (overall P ¼ 0.922). Transient
myocardial ischaemia episodes decreased by .66% in all cohorts,
with .50% of patients becoming TMI-free at the ﬁnal visit in all
three groups (Figure 3). Additionally, the median duration of the
TMI episodes decreased by .75% in all three groups. There
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virtual elimination of ischaemic events by Week 18; atorvastatin
was as effective as amlodipine (Figure 3).
At baseline, the circadian pattern for TMI was observed in all
three arms. By Week 18, there was a marked reduction in ischae-
mic events over 24 h in all three arms (P , 0.001 vs. baseline for all
three cohorts), with little additional reductions recorded between
Weeks 18 and 26 (Figure 4).
Diary data
The mean number of diary reported angina attacks/week in all
three arms decreased signiﬁcantly from baseline by Week 18
(P , 0.001 for each arm) and the effects were maintained at
Week 26 (P , 0.001 for each arm; Figure 5A). Similarly, the
reported use of nitroglycerin tablets was reduced signiﬁcantly
during these periods (P , 0.001 for each arm, baseline vs. Week
18 and vs. Week 26; Figure 5B). The change in number of
Figure 2 Flow of participants through the trial. MITT, modiﬁed intent-to-treat.
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Table 1 Baseline characteristics
Amlodipine
a
(n 5 103)
Atorvastatin
a
(n 5 104)
Amlodipine 1 atorvastatin
a
(n 5 104)
Age, mean (SD) (years) 61.4 (9.0) 62.5 (8.6) 62.8 (8.7)
Weight, mean (SD) (kg) 78.9 (10.9) 81.0 (12.9) 79.3 (11.9)
Diabetes, n (%) 29 (28.2) 23 (22.1) 26 (25.0)
Hypertension, n (%) 72 (69.9) 83 (79.8) 72 (69.2)
Hyperlipidaemia, n (%) 75 (72.8) 82 (78.8) 84 (80.8)
Previous MI, n (%) 53 (51.5) 59 (56.7) 62 (59.6)
TC, mean (SD) (mmol/L) 6.13 (1.0) 6.16 (1.0) 5.93 (1.1)
LDL-C, mean (SD) (mmol/L) 3.9 (1.2) 4.0 (1.1) 3.9 (0.9)
HDL-C, mean (SD) (mmol/L) 1.2 (0.4) 1.3 (0.3) 1.3 (0.3)
TG, mean (SD) (mmol/L) 2.1 (1.2) 1.8 (0.8) 1.9 (0.9)
SBP, mean (SD) (mmHg) 131.7 (12.2) 135.0 (13.0) 131.9 (11.8)
DBP, mean (SD) (mmHg) 80.0 (6.3) 81.4 (6.8) 80.4 (6.4)
DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; SBP, systolic blood pressure;
SD, standard deviation; TC, total cholesterol; TG, triglycerides.
aThere was no statistical difference between treatment groups for the baseline characteristics with the exception of TG (P , 0.05).
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dipine and atorvastatin arms (P ¼ 0.05).
Bicycle exercise testing
During the bicycle exercise test, many subjects did not have angina
or ST depression and stopped the test because of fatigue. Since the
time to angina or ST depression for many subjects was censored to
their total exercise time, the exercise test result may not reﬂect
the actual treatment effect on the time to angina or ST depression.
In the analysis of the time to onset of angina or the time to onset
of ST depression using the log-rank test (Table 3), there were no
statistically signiﬁcant differences among the three treatment
groups at the end of study. In each of the three treatment
groups, 62–66% of patients had angina at baseline and this was
reduced by  50% at Weeks 18 and 26. The proportion of patients
with ST depression at baseline was between 33 and 40% and this
was reduced by  25–50% at Weeks 18 and 26.
.................................. .................................. ...................................
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Table 2 Antihypertensive and anti-anginal use before and during the study by treatment arm
Amlodipine (n 5 103) Atorvastatin (n 5 104) Amlodipine 1 atorvastatin
(n 5 104)
Before During Before During Before During
b-Blockers, n (%) 79 (76.7) 79 (76.7) 89 (85.6) 89 (85.6) 83 (79.8) 83 (79.8)
ACE-inhibitors, n (%) 57 (55.3) 57 (55.3) 64 (61.5) 65 (62.5) 55 (52.9) 55 (52.9)
Diuretics, n (%) 17 (16.5) 17 (16.5) 25 (24.0) 27 (26.0) 21 (20.2) 22 (21.2)
ARBs, n (%) 2 (1.9) 2 (1.9) 4 (3.9) 4 (3.9) 3 (2.9) 3 (2.9)
Other antihypertensive
combinations, n (%)
9 (8.7) 4 (3.9) 12 (11.5) 7 (6.7) 14 (13.5) 8 (7.7)
Anti-anginal therapy, n (%) 67 (65.0) 67 (65.0) 74 (71.2) 74 (71.2) 62 (59.6) 60 (57.7)
ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Figure 3 Median number of transient myocardial ischaemia
episodes/week, recorded by ambulatory electrocardiographic
48 h monitoring. **P , 0.001 vs. baseline. TMI, transient myocar-
dial ischaemia.
Figure 4 Twenty-four-hour circadian patterns during ambulat-
ory electrocardiographic monitoring for the three treatment
groups.
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At Week 26, there was no signiﬁcant change in high-sensitivity
C-reactive protein in the patients who received amlodipine mono-
therapy. In contrast, high-sensitivity C-reactive protein fell signiﬁ-
cantly at Weeks 18 and 26 for atorvastatin or amlodipine +
atorvastatin (Figure 6). There were no or minimal changes in
amyloid-A or interleukin-6 at either time point for any arm. The
median for interleukin-6 was 4.99 for all treatment arms at baseline
and at the two subsequent visits. The interpretation of these
results is limited by the large number of subjects with interleukin-6
below the minimum level of detection for the assay. Likewise, base-
line values for amyloid-A were low and changes for amyloid-A
were modest (range 20.01 to 20.05) and non-signiﬁcant.
Lipids and blood pressure
Asexpected,thereweresigniﬁcantlygreaterdecreasesintotalcholes-
terol, LDL-C, and triglycerides at Week 26 in patients who received
atorvastatin(monotherapyorincombination)comparedwithamlodi-
pine monotherapy (P , 0.001). Low-density lipoprotein cholesterol
reduction to Week 26 [mean (SD)] in the amlodipine cohort was
20.39 (46.4) mg/dL [20.01 (1.2) mmol/L] compared with 277.3
(38.7) mg/dL [22.0 (1.0) mmol/L] with atorvastatin monotherapy
and 281.2 (38.7) mg/dL [22.1 (1.0) mmol/L] for amlodipine + ator-
vastatin. Similarly, in this population with well-controlled blood
pressure, reductions in SBP were slightly greater with amlodipine.
This did not reach statistical signiﬁcance [mean (SD) reduction
in SBP from baseline to Week 26 with amlodipine, 29.12
(14.0) mmHg; atorvastatin, 26.85 (14.8) mmHg; amlodipine +
atorvastatin, 28.54 (12.4) mmHg; P ¼ 0.42]. Results from a stepwise
regressionmodelshowthattherewasnorelationshipbetweenLDL-C
and blood pressure reduction and changes in measures of TMI.
Relationship between transient ischaemia
and high-sensitivity C-reactive protein
In the patients who received atorvastatin, a reduction in TMI was
accompanied by a decrease in high-sensitivity C-reactive protein
[median 20.8 mg/L, P , 0.001 (Pearson’s correlation coefﬁcient
0.17, P ¼ 0.13) in the atorvastatin arm; and 20.4 mg/L, P ,
0.001 (Pearson’s correlation coefﬁcient 0.21, P ¼ 0.05) for
amlodipine + atorvastatin]. This was not observed in those
patients who received amlodipine monotherapy, in whom there
was no systematic change in high-sensitivity C-reactive protein
associated with ischaemia reduction [median 0.2 mg/L, P ¼ 0.113
(Pearson’s correlation coefﬁcient 20.02, P ¼ 0.84); Figure 7].
Safety and adverse events
The incidence of all-causality adverse events was similar in all three
arms with similar low discontinuation rates. Approximately 24% of
patients experienced an adverse event. The majority of events
(75.4%) were mild or moderate, and only 4.2% of subjects discon-
tinued due to an adverse event. Peripheral oedema was the only
treatment-related adverse event that occurred in .2% of patients,
and this occurred exclusively in those who received amlodipine
(6.8% in the monotherapy arm and 10.6% in the combination
arm, P ¼ 0.46). There was one case of myalgia reported in each
group with no elevation in creatine phosphokinase levels. Transi-
tory elevations in alanine aminotransferase (.3× upper limit of
normal) were observed in 1% of participants (one subject per
arm). No hepatic adverse events were reported.
Discussion
This study demonstrated that in patients with stable angina and
CAD, atorvastatin virtually eliminated episodes of TMI during
normal daily life, both with and without symptoms. Atorvastatin
was as effective as the well-established anti-anginal therapy, amlo-
dipine. Because of the powerful effect of each agent alone, it was
not possible to test whether combination therapy with both amlo-
dipine and atorvastatin offered additional effectiveness over the
individual agents. However, the impact of atorvastatin and amlodi-
pine on the inﬂammatory marker high-sensitivity C-reactive
protein differed, suggesting that the anti-ischaemic effects were
not achieved by the same mechanisms.
Vascular effects of amlodipine and statins
We have previously demonstrated reduction in TMI in patients
with stable CAD using amlodipine monotherapy and in combi-
nation with other agents.
4,6 This is most likely due to direct arterial
vasodilatation with improved coronary ﬂow and systemic after-
load reduction.
12,13 There is increasing interest, however, in target-
ing further the dysfunctional vascular biology of atherosclerosis, as
this may underlie both the disturbances of coronary blood ﬂow in
Figure 5 (A) Mean angina attacks/week and (B) mean number
of nitroglycerin tablets/week, based on patients’ diaries.
**P , 0.001 vs. baseline;
†P , 0.05 change from baseline
between groups.
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comes.
14,15 Statins show a variety of vascular effects in addition
to LDL-C lowering, but the clinical relevance of these ‘pleiotropic’
actions has been controversial.
7,16,17 We now show, in a large ran-
domized trial, that atorvastatin reduces one of the most common
clinical manifestations of atherosclerosis, TMI with and without
accompanying angina pectoris, in association with high-sensitivity
C-reactive protein lowering. Our objective measurements of
TMI, based on ST-segment depression during AECG monitoring,
were mirrored by similar reductions in both angina and nitrogly-
cerin use recorded in independent patient diary data. These
rapid changes are unlikely to be due solely to beneﬁcial remodel-
ling of the underlying arterial stenoses and, furthermore, were not
related to degree of LDL-C lowering. The substantial reductions in
ischaemic activity achieved by the treatments provide mechanistic
support for the ﬁndings of the Clinical Outcomes Utilizing Revas-
cularization and Aggressive Drug Evaluation (COURAGE) trial, in
which angina and myocardial ischaemia are signiﬁcantly reduced
from baseline in the medically managed groups.
1
Effects of atorvastatin
Previous studies in patients with acute coronary syndromes or after
MIhaveshownsimilarrapidbeneﬁtsinischaemiceventsormortality
using high-dose atorvastatin.
9,10 Patients were titrated rapidly to the
maximum dose of 80 mg so that we were unable to determine
whether a lower dose would have been effective in reducing myo-
cardial ischaemia, as has been reported for clinical outcomes.
18,19
We included a combination arm to explore the potential beneﬁt
for dual therapy with amlodipine and atorvastatin and powered
our study on the basis of a modest anti-ischaemic effect from ator-
vastatin. The unexpectedly large reduction in TMI observed with
atorvastatin (52% of patients were rendered ischaemia-free),
however, precluded the possibility of investigating potential additive
or synergistic actions of the two drugs in combination.
Mechanisms of action
Although the beneﬁt on TMI was seen with both amlodipine and
atorvastatin, the underlying mechanisms are likely to differ. High-
........................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 3 Time to onset of angina and ST depression during bicycle exercise testing at baseline and at Weeks 18 and 26
Amlodipine
(A) (N 5 93)
Atorvastatin
(B) (N 5 91)
Amlodipine 1
atorvastatin (C) (N 5 99)
Overall
P-value
a
Pair-wise P-values
b
A vs. B A vs. C B vs. C
Time to onset of angina (s)
c
Baseline
n 93 91 99
Median (s) 500 485 536
Angina (%) 62.4 61.5 65.7 0.817 0.524 0.837 0.668
Week 18
n 93 91 97
Median (s) 520 552 555
Angina (%) 33.3 36.3 29.3 0.475 0.839 0.252 0.315
Week 26
n 93 91 99
Median (s) 509 554 540
Angina (%) 32.3 29.7 26.3 0.444 0.365 0.243 0.714
Time to onset of ST depression (s)
c
Baseline
n 92 88 97
Median (s) 524 487 540
ST depression (%) 33.3 42.9 40.4 0.673 0.333 0.653 0.711
Week 18
n 92 88 95
Median (s) 517 536 548
ST depression (%) 29.0 38.5 20.2 0.026 0.341 0.079 0.006
Week 26
n 92 88 97
Median (s) 517 540 540
ST depression (%) 25.8 31.9 25.3 0.649 0.583 0.709 0.366
N, number of subjects with a baseline and at least one post-baseline observation; n, number of subjects with data at a given visit.
aBased on extended log-rank test for overall comparison among three treatment groups.
bBased on log-rank test for pair-wise comparison between two treatment groups.
cIf a subject did not have angina or ST depression, then the time to onset of angina or time to onset of ST depression was censored at the total exercise time.
J.E. Deanﬁeld et al. 2656sensitivity C-reactive protein was reduced only in the atorvastatin
arms (as previously recorded in other populations), and no change
was seen accompanying TMI reduction with amlodipine.
20 This
clearly does not imply a causal role for C-reactive protein in the
pathogenesis of TMI or angina.
Statins are known to reduce vascular inﬂammation and oxidative
stress and improve endothelial function.
7 All of these processes
may contribute to disturbances in coronary ﬂow regulation
during normal daily life and lead to TMI.
14,21 Our study was not
designed to examine the quantitative relation between the
degree of LDL-C lowering or inﬂammatory markers and change
in activity of TMI. We cannot therefore draw conclusions about
the relative contribution of cholesterol lowering and ‘pleiotropic’
effects on the substantial improvement in ischemia seen with ator-
vastatin therapy.
Patient population and study design
Our trial included patients similar to those frequently encountered
by physicians in clinical practice. They were aged 39–82 years,
most were already receiving standard anti-anginal and anti-platelet
medications, and had well-controlled blood pressure.
4,6 We
designed our study to compare the effects of two drugs with differ-
ent actions and their combination. We did not include a placebo
arm for comparison with the active therapies, as it was considered
unethical by the investigator sites. Previous studies have reported
substantial reduction in ischaemia and angina in placebo groups
of patients experiencing angina and coronary disease due in part
to ‘regression to the mean’. We set the threshold for ischaemic
activity required for inclusion in the study at a lower level than
in previous studies using AECG monitoring to reduce the likeli-
hood of the improvements being due to this phenomenon.
All ECG analyses were conducted by core lab staff who were
blinded to therapy assignment and treatment phase. Patients
were recruited on the basis of TMI in normal daily life, which
was also the primary outcome measure. As in our previous
studies, interpretable data were obtained on episodes of ST
depression from the majority of patients, with only 9.3% of
randomized subjects excluded for technical reasons.
4,6 We also
undertook bicycle tests as a secondary measure, but this proved
difﬁcult to standardize and interpret largely due to the patients’
good total exercise time at baseline and the variations between
centres in the quality of records and conduct of the test.
Figure 6 Change from baseline in high-sensitivity C-reactive
protein by treatment group. *P , 0.05 vs. baseline; **P , 0.001
vs. baseline;
†P , 0.001 for change from baseline between treat-
ment groups.
Figure 7 Change in number of transient myocardial
ischaemia episodes during ambulatory electrocardiographic
monitoring and high-sensitivity C-reactive protein in the three
groups. TMI, transient myocardial ischaemia; AECG, ambulatory
electrocardiogram.
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Medical therapy strategies are now moving towards concurrent
reduction in multiple risk factors, such as blood pressure and
LDL-C, because of emerging evidence for outcome beneﬁt for this
approach over individual risk-factor control.
22 This may be due to
beneﬁts on the common vascular consequences of risk factors. We
now show additional beneﬁts of statin therapy beyond lipid lowering
in a frequently encountered patient population, with substantial
reduction in symptomatic and asymptomatic ischaemia. Although
wedidnotdemonstrateadditionalbeneﬁtswithamlodipineandator-
vastatin combination therapy, future studies in patients with more
severeischaemia,notcontrolled byasingleagent,aswellasoflower-
dose combination treatment, will be instructive.
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Successful off-pump device closure of an isolated perimembraneous
ventricular septal defect using a series of six occluders in a 5 kg infant
via a minimally invasive approach
Qin Wu1, Quansheng Xing1*, Zuoyuan Chen2, Silin Pan1, and Yueyi Ren1
1Heart Center, Children’s Hospital of Qingdao University, Qingdao, Shandong 266011, China; and
2Cardiology Department, Teaching Hospital of Qingdao University,
Qingdao, Shandong 266003, China
* Corresponding author. Tel: +86 136 0642 6893, Fax: +86 532 8285 7650, Email: xingqs0532@163.com
A3-month-oldfemaleof5 kgpresentedwitha4.23 mm
isolated perimembranous ventricular septal defect
(pmVSD) which was conﬁrmed by transoesophageal
echocardiography (TEE) (Panel A). Before that, she
had suffered from pneumonia twice. Systolic murmurs
of Grade 3 could be heard in the third intercostal
space, with intense pulmonary second heart sound. As
determined with transthoracic echocardiography
(TTE) analysis, the dimensions of the pmVSD were
4.5 mm, with enlarged left atria and ventricles. A
46 mmHg pulmonary artery systolic pressure was esti-
mated by TTE. Cardiomegaly (cardiothoracic ratio:
0.65) and pulmonary congestion were demonstrated
on chest X-ray ﬁlm. All the above features strongly
indicated early closure of the pmVSD.
We chose the perventricular device closure of VSD
under TEE without cardiopulmonary bypass through
2.5 cm incision, inferior sternotomy. The mechanism
of the procedure (Panel B), the devices, and the deliv-
ery system (Panel C) were described previously (Xing
et al. J Thorac Cardiovasc Surg 2009;137:556–559).
The devices, including symmetric pmVSD occluders
(S-pmVSDO) and asymmetric pmVSD (A-pmVSDO), were supplied by Shenzhen Lifetech Scientiﬁc Co., Ltd (Panel Da, b, and e)
or Shanghai Xingzhuangjiyi Alloy Material Co., Ltd (Panel Dc, d, and f).
A 6 mm S-pmVSDO from Shenzhen (Panel Da) was chosen initially. The defect was completely closed but mild aortic regurgitation
(AR) was detected by TEE (Panel E). The device was retrieved into the loading sheath and removed. A 5 mm S-pmVSDO from Shen-
zhen (Panel Db) was chosen to replace the previous one (Panel Da). There was no AR, but mild residual shunt through the waist of the
device appeared (Panel F). Then, a 5 mm S-pmVSDO and a 5 mm A-pmVSDO from Shanghai (Panel Dc and d) were used. Similar
results were obtained (Panels G and H). Then, a 6 mm A-pmVSDO from Shenzhen (Panel De) was used, but this time, a different
mild residual shunt from the upper side of the device was detected by TEE (Panel I). Finally, a satisfactory result was obtained with
the use of a 6 mm A-pmVSDO from Shanghai (Panel Df). After multiplane TEE assessment for the absence of residual shunting,
left and right ventricular outlet tracts obstruction, valve interference, and arrhythmia (Panel J), the device was released. The whole pro-
ceduretook126 min,andthebabywasextubated2 haftertheoperation.Antibioticsweregivenintravenouslyfor3days,andthebabywas
put on aspirin daily (3 mg/kg) after extubation. Before discharge and at the ﬁrst month follow-up, the patients received examinations as
follows: electrocardiogram, chest X-ray, and echocardiography. No complication has been detected at the time of this writing.
Perventricular device closure of VSD technique simpliﬁes VSD closure and there is no age or body weight limitation. It may be a
new hybrid approach, requiring mainly collaboration between the TEE and cardiac doctors. More importantly, it is feasible to repeat
the deployment of devices of different size or kind until an optimal result is achieved in one case.
The authors wish to express their thanks for the support from the Children’s Hospital and Teaching Hospital of Qingdao University.
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